Clinical Trial: HEALEY ALS Platform Trial - Regimen I NUZ-001

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07410806) titled 'HEALEY ALS Platform Trial - Regimen I NUZ-001' on Feb. 08.

Brief Summary: The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with ALS.

Study Start Date: Feb. 16

Study Type: INTERVENTIONAL

Condition: Amyotrophic Lateral Sclerosis (ALS)

Intervention: DRUG: NUZ-001

NUZ-001 is administered orally once daily for 36 weeks.

DRUG: Matching placebo

Matching placebo is administered orally once daily for 36 weeks....